Abbott Laboratories Hovers Near 52-Week Low as Shares Slide to $84.38

May 15, 2026

By TrendSpider Editor

ABT market update based on latest price_mover data.

Abbott Laboratories Hovers Near 52-Week Low as Shares Slide to $84.38

Abbott Laboratories shed 0.60% on Friday, May 15, 2026, with shares settling at $84.38 and sitting uncomfortably close to the stock's 52-week low of $81.97. The current price sits far below the 52-week high of $139.05, reflecting a prolonged drawdown that has wiped out a substantial portion of the stock's value over the past year. With the gap between current price and yearly peak exceeding $54 per share, ABT is in deep technical distress.

Key Drivers of the ABT Stock Move

Main Catalyst: ABT slipped 0.60% in Friday's session, continuing its downward drift toward the 52-week low of $81.97. Thursday's session saw the stock trade between $84.05 and $85.265, a range of just over $1.21, signaling compressed volatility and limited buying conviction near these depressed levels.
Bull Case: The stock is trading within roughly $2.41 of its 52-week low of $81.97, which historically can attract value-oriented and mean-reversion buyers who view this level as technical support. Any stabilization or positive catalyst from this zone could produce a sharp snapback given the wide distance from the $139.05 yearly high.
Bear Case: The proximity to the 52-week low tells a bearish story on its own. ABT has lost enormous ground from $139.05 and the current session's modest decline suggests sellers remain in control. A breach of $81.97 would mark a new multi-year low and could accelerate further downside as technical support evaporates.

The forward setup for ABT is cautious at best. The stock is grinding lower with no visible floor confirmed above the $81.97 yearly low, and the narrow intraday range from the prior session between $84.05 and $85.265 points to a market that is neither aggressively buying the dip nor panicking to the downside yet. Traders will be watching closely to see whether $81.97 holds as a hard floor or becomes the next level to break. Without a meaningful positive catalyst, whether from earnings, regulatory news, or a broader market rally, ABT appears vulnerable to further erosion in the near term.

ABT Relative Performance

ABT's current price of $84.38 represents a decline of roughly 39% from its 52-week high of $139.05, a far steeper drawdown than what most large-cap healthcare and medical device peers have experienced over the same period. The stock's positioning near the bottom of its annual range suggests it has significantly underperformed its sector during the past twelve months. While the broader medical device space has faced headwinds from rate sensitivity and shifting healthcare spending priorities, ABT's nearness to $81.97 stands out as a warning sign relative to peers that have maintained healthier distances from their own yearly lows.

ABT Seasonality

Historically, mid-May tends to mark a transitional period for large-cap healthcare names as investors reposition ahead of summer. For stocks already under pressure near 52-week lows, this seasonal window has not reliably provided a lift, and momentum often remains skewed to the downside until a concrete catalyst emerges.